PECAZINE HYDROCHLORIDE

US Previously Marketed

First approved in 1957

Details

Stereochemistry	RACEMIC
Molecular Formula	C19H22N2S.ClH
Molecular Weight	346.917
Optical Activity	( + / - )
Defined Stereocenters	0 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

Cl.CN1CCCC(CN2C3=C(SC4=C2C=CC=C4)C=CC=C3)C1

InChI

InChIKey=RLCFKYRNUBRPIK-UHFFFAOYSA-N

InChI=1S/C19H22N2S.ClH/c1-20-12-6-7-15(13-20)14-21-16-8-2-4-10-18(16)22-19-11-5-3-9-17(19)21;/h2-5,8-11,15H,6-7,12-14H2,1H3;1H

HIDE SMILES / InChI

Molecular Formula	C19H22N2S
Molecular Weight	310.456
Charge	0
Count

Stereochemistry	RACEMIC
Additional Stereochemistry	No
Defined Stereocenters	0 / 1
E/Z Centers	0
Optical Activity	( + / - )

Molecular Formula	ClH
Molecular Weight	36.461
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/23946259 | https://www.ncbi.nlm.nih.gov/pubmed/14405543

PECAZINE is a phenothiazine derivative that was used as an antipsychotic. It is also an allosteric inhibitor of MALT1 paracaspase activity.

CNS Activity

Approval Year

Doses

Dose	Population	Adverse events
75 mg 3 times / day multiple, oral Recommended Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/14405543 Page: p.729	unhealthy, 20-59 n = 33 Health Status: unhealthy Condition: schizophrenia Age Group: 20-59 Sex: F Population Size: 33 Sources: https://pubmed.ncbi.nlm.nih.gov/14405543 Page: p.729	Disc. AE: Agranulocytosis... AEs leading to discontinuation/dose reduction: Agranulocytosis (3%) Sources: https://pubmed.ncbi.nlm.nih.gov/14405543 Page: p.729
50 mg 3 times / day multiple, oral Recommended Dose: 50 mg, 3 times / day Route: oral Route: multiple Dose: 50 mg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/13377680	unhealthy, 35 n = 1 Health Status: unhealthy Condition: depisssion Age Group: 35 Sex: F Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/13377680	Disc. AE: Agranulocytosis... AEs leading to discontinuation/dose reduction: Agranulocytosis Sources: https://pubmed.ncbi.nlm.nih.gov/13377680
300 mg multiple, oral Recommended Dose: 300 mg Route: oral Route: multiple Dose: 300 mg Sources: https://pubmed.ncbi.nlm.nih.gov/13436861 Page: p.80	unhealthy, 37.1±1.5 n = 50 Health Status: unhealthy Condition: schizophrenia Age Group: 37.1±1.5 Sex: M+F Population Size: 50 Sources: https://pubmed.ncbi.nlm.nih.gov/13436861 Page: p.80	Disc. AE: Cycloplegia... AEs leading to discontinuation/dose reduction: Cycloplegia (4%) Sources: https://pubmed.ncbi.nlm.nih.gov/13436861 Page: p.80
900 mg multiple, oral Highest studied dose Dose: 900 mg Route: oral Route: multiple Dose: 900 mg Sources: https://pubmed.ncbi.nlm.nih.gov/13444479 Page: p.144	unhealthy n = 2 Health Status: unhealthy Condition: schizophrenia Population Size: 2 Sources: https://pubmed.ncbi.nlm.nih.gov/13444479 Page: p.144	Sources: https://pubmed.ncbi.nlm.nih.gov/13444479 Page: p.144
25 mg 3 times / day multiple, oral Studied dose Dose: 25 mg, 3 times / day Route: oral Route: multiple Dose: 25 mg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/13444479 Page: p.144	unhealthy n = 2 Health Status: unhealthy Condition: schizophrenia Population Size: 2 Sources: https://pubmed.ncbi.nlm.nih.gov/13444479 Page: p.144	Disc. AE: Jaundice... AEs leading to discontinuation/dose reduction: Jaundice Sources: https://pubmed.ncbi.nlm.nih.gov/13444479 Page: p.144

AEs

AE	Significance	Dose	Population
Agranulocytosis	3% Disc. AE	75 mg 3 times / day multiple, oral Recommended Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/14405543 Page: p.729	unhealthy, 20-59 n = 33 Health Status: unhealthy Condition: schizophrenia Age Group: 20-59 Sex: F Population Size: 33 Sources: https://pubmed.ncbi.nlm.nih.gov/14405543 Page: p.729
Agranulocytosis	Disc. AE	50 mg 3 times / day multiple, oral Recommended Dose: 50 mg, 3 times / day Route: oral Route: multiple Dose: 50 mg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/13377680	unhealthy, 35 n = 1 Health Status: unhealthy Condition: depisssion Age Group: 35 Sex: F Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/13377680
Cycloplegia	4% Disc. AE	300 mg multiple, oral Recommended Dose: 300 mg Route: oral Route: multiple Dose: 300 mg Sources: https://pubmed.ncbi.nlm.nih.gov/13436861 Page: p.80	unhealthy, 37.1±1.5 n = 50 Health Status: unhealthy Condition: schizophrenia Age Group: 37.1±1.5 Sex: M+F Population Size: 50 Sources: https://pubmed.ncbi.nlm.nih.gov/13436861 Page: p.80
Jaundice	Disc. AE	25 mg 3 times / day multiple, oral Studied dose Dose: 25 mg, 3 times / day Route: oral Route: multiple Dose: 25 mg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/13444479 Page: p.144	unhealthy n = 2 Health Status: unhealthy Condition: schizophrenia Population Size: 2 Sources: https://pubmed.ncbi.nlm.nih.gov/13444479 Page: p.144

Sourcing

Vendor/Aggregator	ID	URL
001 Chemical	DY562589	https://www.001chemical.com/chem/60-89-9
Alfa Chemistry	60-89-9	https://www.alfa-chemistry.com/cas_60-89-9.htm
Aurora Fine Chemicals LLC	K02.237.593	http://online.aurorafinechemicals.com/info?ID=K02.237.593
Chem Scene	CS-0081367	http://www.chemscene.com/60-89-9.html
Chemspace	CSSS00102561680	https://chem-space.com/CSSS00102561680
Lab Network	LN01302729	https://labnetwork.com/frontend-app/p/#!/moleculedetails/LN01302729
Matrix Scientific	176622	https://www.matrixscientific.com/176622.html
MedChem Express	HY-121282	https://www.medchemexpress.com/mepazine.html
Molcore	MC562589	https://www.molcore.com/product/60-89-9
Smolecule	S538872	http://www.smolecule.com/products/s538872
THE BioTek	bt-278398	https://www.thebiotek.com/product/inhibitors/bt-278398
VladaChem	VL130984	https://www.vladachem.com/product.php?products=60-89-9
Yuhao Chemical	SY0043	http://www.chemyuhao.com/60-89-9.html
eNovation Chemicals	D931422	https://www.enovationchem.com/ProductDetails.asp?ProductID=D931422
mcule	MCULE-4399173403	https://mcule.com/MCULE-4399173403/

PubMed

Title	Date	PubMed
Changes in clinical trials methodology over time: a systematic review of six decades of research in psychopharmacology.	2010 Mar 3	20209133
Profiling of a prescription drug library for potential renal drug-drug interactions mediated by the organic cation transporter 2.	2011 Jul 14	21599003

Substance Class	Chemical Created by `admin` on `Fri Dec 15 15:20:31 GMT 2023` Edited by `admin` on `Fri Dec 15 15:20:31 GMT 2023`
Record UNII	TIW15Q5R21
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

PECAZINE HYDROCHLORIDE

Common Name

English

PECAZINE MONOHYDROCHLORIDE

Common Name

English

10H-PHENOTHIAZINE, 10-((1-METHYL-3-PIPERIDINYL)METHYL)-, HYDROCHLORIDE (1:1)

Systematic Name

English

10H-PHENOTHIAZINE, 10-((1-METHYL-3-PIPERIDINYL)METHYL)-, MONOHYDROCHLORIDE

Common Name

English

PHENOTHIAZINE, 10-((1-METHYL-3-PIPERIDYL)METHYL)-, MONOHYDROCHLORIDE

Common Name

English

MEPAZINE CHLORIDE

Common Name

English

NSC-64076

Code

English

MEPAZINE HCL

Common Name

English

MEPAZINE HYDROCHLORIDE

Common Name

English

(±)-MEPAZINE HYDROCHLORIDE

Common Name

English

MEPAZINE HYDROCHLORIDE, (±)-

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C66883